359 related articles for article (PubMed ID: 34615636)
1. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Furie RA; Aroca G; Cascino MD; Garg JP; Rovin BH; Alvarez A; Fragoso-Loyo H; Zuta-Santillan E; Schindler T; Brunetta P; Looney CM; Hassan I; Malvar A
Ann Rheum Dis; 2022 Jan; 81(1):100-107. PubMed ID: 34615636
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
[TBL] [Abstract][Full Text] [Related]
3. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
[TBL] [Abstract][Full Text] [Related]
6. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial.
Rovin BH; Furie RA; Ross Terres JA; Giang S; Schindler T; Turchetta A; Garg JP; Pendergraft WF; Malvar A
Arthritis Rheumatol; 2024 Feb; 76(2):247-254. PubMed ID: 37947366
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH; Solomons N; Pendergraft WF; Dooley MA; Tumlin J; Romero-Diaz J; Lysenko L; Navarra SV; Huizinga RB;
Kidney Int; 2019 Jan; 95(1):219-231. PubMed ID: 30420324
[TBL] [Abstract][Full Text] [Related]
8. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Jayne D; Rovin B; Mysler EF; Furie RA; Houssiau FA; Trasieva T; Knagenhjelm J; Schwetje E; Chia YL; Tummala R; Lindholm C
Ann Rheum Dis; 2022 Apr; 81(4):496-506. PubMed ID: 35144924
[TBL] [Abstract][Full Text] [Related]
9. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
12. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Jayne DR; Steffgen J; Romero-Diaz J; Bajema I; Boumpas DT; Noppakun K; Amano H; Gomez HM; Satirapoj B; Avihingsanon Y; Chawanasuntorapoj R; Madero M; Naumnik B; Recto R; Fagan N; Revollo I; Wu J; Visvanathan S; Furie R
Arthritis Rheumatol; 2023 Nov; 75(11):1983-1993. PubMed ID: 37192040
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
[TBL] [Abstract][Full Text] [Related]
15. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
Ginzler EM; Wax S; Rajeswaran A; Copt S; Hillson J; Ramos E; Singer NG
Arthritis Res Ther; 2012 Feb; 14(1):R33. PubMed ID: 22325903
[TBL] [Abstract][Full Text] [Related]
16. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
17. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M
Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis.
Li F; Cui W; Huang G; Tian Y; Zhang X; He W; Sun Q; Zhao X; Zhao Y; Li D; Liu X; Liu X
Clin Exp Med; 2023 Nov; 23(7):3011-3018. PubMed ID: 37462818
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Redfield RR; Jordan SC; Busque S; Vincenti F; Woodle ES; Desai N; Reed EF; Tremblay S; Zachary AA; Vo AA; Formica R; Schindler T; Tran H; Looney C; Jamois C; Green C; Morimoto A; Rajwanshi R; Schroeder A; Cascino MD; Brunetta P; Borie D
Am J Transplant; 2019 Nov; 19(11):3035-3045. PubMed ID: 31257724
[TBL] [Abstract][Full Text] [Related]
20. [The treatment of lupus nephritis, between consolidated strategies and new therapeutic options: a narrative review].
Fontana F; Alfano G; Cappelli G
G Ital Nefrol; 2021 Aug; 38(4):. PubMed ID: 34469086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
